medicina58巻1号

2021年01月発行

特集 エキスパートに学ぶ—最新の循環器治療薬の使い方 知っておくべき10種類の循環器治療薬と治療法

高トリグリセリド血症に対する新規治療薬：パルモディア^®

著者： 吉田尚史¹ 山下智也² 平田健一¹

所属機関： ¹神戸大学大学院医学研究科内科学講座循環器内科学分野 ²神戸大学医学部附属病院循環器内科

ページ範囲：P.64 - P.68

Question 1
高トリグリセリド（TG）血症は冠動脈疾患のリスクになりますか？

参考文献

1）Yokoyama M, et al：Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients（JELIS）；A randomised open-label, blinded endpoint analysis. Lancet 369：1090-1098, 2007

2）Kajikawa M, et al：Target of triglycerides as residual risk for cardiovascular events in patients with coronary artery disease；Post hoc analysis of the FMD-J Study A. Circ J 83：1064-1071, 2019

3）Otsuka T, et al. Dyslipidemia and the risk of developing hypertension in a working-age male population. Am Heart Assoc 5：e003053, 2016

4）Ye X, et al ：Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus；A systematic review and meta-analysis of prospective studies. Cardiovas Diabetol 18：48, 2019

5）Scott R, et al：Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome；The Fenofibrate Intervention and Event Lowering in Diabetes（FIELD）study. Diabetes Care 32：493-498, 2009

6）Bruckert E, et al ：Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile；A systematic review and meta-analysis. Cardiovasc Pharmacol 57：267-272, 2011

7）Marston NA, et al：Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes. Circulation 140：1308-1317, 2019

8）Pradhan AD, et al：Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes（PROMINENT）study. Am Heart J 206：80-93, 2018

9）Fruchart JC：Selective peroxisome proliferator-activated receptorα modulators（SPPARMα）；The next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol 12：82, 2013

F-fluorodeoxyglucose PET-MRI. Diabetes Care 43：1796-1802, 2020

11）Laufs U, et al：Clinical review on triglycerides. Eur Heart J 41：99-109c, 2019

12）Fujihara K, et al：Impact of body mass index and metabolic phenotypes on coronary artery disease according to glucose tolerance status. Diabetes Metab 43：543-546, 2017

13）Tesfaye S, et al：Vascular risk factors and diabetic neuropathy. N Engl J Med 352：341-350, 2005

14）Sacks FM, et al：Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus. Circulation 129：999-1008, 2014

15）Frick MH, et al：Helsinki Heart Study；Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317：1237-1245, 1987

16）Rubins HB, et al：Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341：410-418, 1999

17）Bezafibrate Infarction Prevention（BIP）study：Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102：21-27, 2000

18）Keech A, et al：Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus（the FIELD study）；Randomised controlled trial. Lancet 366：1849-1861, 2005

19）ACCORD Study Group：Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362：1563-1574, 2010